These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 22015859)

  • 21. Augmentation of venlafaxine with bupropion: risks associated with a triple monoamine reuptake inhibition approach to partially responsive depression.
    Andrade C
    J Clin Psychiatry; 2013 Feb; 74(2):e119-21. PubMed ID: 23473356
    [No Abstract]   [Full Text] [Related]  

  • 22. Comparing the rapidity of response during treatment of major depressive disorder with bupropion and the SSRIs: a pooled survival analysis of 7 double-blind, randomized clinical trials.
    Papakostas GI; Montgomery SA; Thase ME; Katz JR; Krishen A; Tucker VL
    J Clin Psychiatry; 2007 Dec; 68(12):1907-12. PubMed ID: 18162022
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The other face of depression, reduced positive affect: the role of catecholamines in causation and cure.
    Nutt D; Demyttenaere K; Janka Z; Aarre T; Bourin M; Canonico PL; Carrasco JL; Stahl S
    J Psychopharmacol; 2007 Jul; 21(5):461-71. PubMed ID: 17050654
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nortriptyline toxicity secondary to interaction with bupropion sustained-release.
    Weintraub D
    Depress Anxiety; 2001; 13(1):50-2. PubMed ID: 11233461
    [No Abstract]   [Full Text] [Related]  

  • 25. Clinical evidence and potential neurobiological underpinnings of unresolved symptoms of depression.
    Trivedi MH; Hollander E; Nutt D; Blier P
    J Clin Psychiatry; 2008 Feb; 69(2):246-58. PubMed ID: 18363453
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Does early-onset chronic or recurrent major depression impact outcomes with antidepressant medications? A CO-MED trial report.
    Sung SC; Wisniewski SR; Balasubramani GK; Zisook S; Kurian B; Warden D; Trivedi MH; Rush AJ;
    Psychol Med; 2013 May; 43(5):945-60. PubMed ID: 23228340
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness of a quantitative electroencephalographic biomarker for predicting differential response or remission with escitalopram and bupropion in major depressive disorder.
    Leuchter AF; Cook IA; Gilmer WS; Marangell LB; Burgoyne KS; Howland RH; Trivedi MH; Zisook S; Jain R; Fava M; Iosifescu D; Greenwald S
    Psychiatry Res; 2009 Sep; 169(2):132-8. PubMed ID: 19709754
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quality of life in geriatric depression: a comparison of remitters, partial responders, and nonresponders.
    Doraiswamy PM; Khan ZM; Donahue RM; Richard NE
    Am J Geriatr Psychiatry; 2001; 9(4):423-8. PubMed ID: 11739069
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Selective noradrenaline-dopamine reuptake inhibition (SNDRI). More latitude for antidepressive therapy].
    MMW Fortschr Med; 2007 May; 149 Suppl 2():88-9. PubMed ID: 17724976
    [No Abstract]   [Full Text] [Related]  

  • 30. Delirium associated with concomitant use of duloxetine and bupropion in an elderly patient.
    Ma SP; Tsai CJ; Chang CC; Hsu WY
    Psychogeriatrics; 2017 Mar; 17(2):130-132. PubMed ID: 27046219
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of bupropion XL and escitalopram on memory and functional outcomes in adults with major depressive disorder: results from a randomized controlled trial.
    Soczynska JK; Ravindran LN; Styra R; McIntyre RS; Cyriac A; Manierka MS; Kennedy SH
    Psychiatry Res; 2014 Dec; 220(1-2):245-50. PubMed ID: 25124683
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of treatment with bupropion on EEG sleep: relationship to antidepressant response.
    Ott GE; Rao U; Lin KM; Gertsik L; Poland RE
    Int J Neuropsychopharmacol; 2004 Sep; 7(3):275-81. PubMed ID: 15122973
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An open-label, rater-blinded, 8-week trial of bupropion hydrochloride extended-release in patients with major depressive disorder with atypical features.
    Seo HJ; Lee BC; Seok JH; Jeon HJ; Paik JW; Kim W; Kwak KP; Han C; Lee KU; Pae CU
    Pharmacopsychiatry; 2013 Sep; 46(6):221-6. PubMed ID: 23963965
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Smoking cessation.
    Frankenburg FR
    JAMA; 2005 Nov; 294(19):2434; author reply 2435. PubMed ID: 16287951
    [No Abstract]   [Full Text] [Related]  

  • 35. Rediscovering trazodone for the treatment of major depressive disorder.
    Fagiolini A; Comandini A; Catena Dell'Osso M; Kasper S
    CNS Drugs; 2012 Dec; 26(12):1033-49. PubMed ID: 23192413
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bupropion: efficacy and safety in the treatment of depression.
    Saiz Ruiz J; Gibert J; Gutiérrez Fraile M; Bobes J; Vallejo J; Iglesias C; Iriarte V
    Actas Esp Psiquiatr; 2011; 39 Suppl 1():1-25. PubMed ID: 22983817
    [No Abstract]   [Full Text] [Related]  

  • 37. Bupropion for depression in schizophrenia.
    Englisch S; Inta D; Eer A; Zink M
    Clin Neuropharmacol; 2010; 33(5):257-9. PubMed ID: 20852411
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bupropion in the management of apathy.
    Corcoran C; Wong ML; O'Keane V
    J Psychopharmacol; 2004 Mar; 18(1):133-5. PubMed ID: 15107198
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Spotlight on bupropion in major depressive disorder.
    Dhillon S; Yang LP; Curran MP
    CNS Drugs; 2008; 22(7):613-7. PubMed ID: 18547129
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Depression treatment in patients with general medical conditions: results from the CO-MED trial.
    Morris DW; Budhwar N; Husain M; Wisniewski SR; Kurian BT; Luther JF; Kerber K; Rush AJ; Trivedi MH
    Ann Fam Med; 2012; 10(1):23-33. PubMed ID: 22230827
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.